Equity InvestmentOct. 2013
Life science startups often face financial and technical difficulties during the course of drug development, especially during the very costly clinical trials. XinTech helps to offset these difficulties by leveraging on the needs and capabilities of Chinese pharmaceutical companies.
Because of high demand and heavily-regulated low supply, blood products in China are increasingly scarce and expensive to obtain. Aware of the massive need for such products in China, XinTech and Vanir ventured into the local market to identify local players.
The Canadian company Sirona Biochem has executed an exclusive license agreement with China's Wanbang Biopharma to develop and commercialize Sirona’s anti-diabetic SGLT2 inhibitor in China.